ConductScience.org, home

Paper40565145

Anti-lymphoma Activity of Acyclic Terpenoids and Its Structure-Activity Relationship: In Vivo, In Vitro, and In Silico Studies.

Calzada F and 5 others. Int J Mol Sci, 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Anti-lymphoma Activity of Acyclic Terpenoids and Its Structure-Activity Relationship: In Vivo, In Vitro, and In Silico Studies. Papers, record 40565145. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40565145

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-lymphoma Activity of Acyclic Terpenoids and Its Structure-Activity Relationship: In Vivo, In Vitro, and In Silico Studies.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2025-06-28
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Calzada FFernandohttps://orcid.org/0000-0003-1851-5988
2Ramírez-Santos JJesicahttps://orcid.org/0000-0002-2673-4366
3Ordoñez-Razo RMRosa Maríahttps://orcid.org/0000-0003-4949-9175
4Valdes MMiguelhttps://orcid.org/0000-0001-7401-303X
5Velázquez CClaudiahttps://orcid.org/0000-0003-0546-5969
6Barbosa EElizabethhttps://orcid.org/0000-0002-7111-7922

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
TerpenesMajor topic
LymphomaMajor topic
Antineoplastic AgentsMajor topic
Antineoplastic Agents, PhytogenicMajor topic
Animals
Molecular Docking Simulation
Mice
Structure-Activity Relationship
Male
Cell Line, Tumor
Mice, Inbred BALB C
Humans
Computer Simulation
Cell Proliferation

Source PubMed

Download CSV of topics

References53

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122294375Overview on the Rule of Five.Curr Protoc Pharmacol2010https://conductscience.org/library/papers/22294375PubMed
227562463The interplay between cell signalling and the mevalonate pathway in cancer.Nat Rev Cancer2016https://conductscience.org/library/papers/27562463PubMed
38882960Analysis of the colonization of unirradiated and irradiated SCID mice by human lymphoma and non-malignant lymphoid cells.Leuk Lymphoma1996https://conductscience.org/library/papers/8882960PubMed
438647086ProTox 3.0: a webserver for the prediction of toxicity of chemicals.Nucleic Acids Res2024https://conductscience.org/library/papers/38647086PubMed
533893803ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties.Nucleic Acids Res2021https://conductscience.org/library/papers/33893803PubMed
638731446In Vivo, In Vitro and In Silico Anticancer Activity of Ilama Leaves: An Edible and Medicinal Plant in Mexico.Molecules2024https://conductscience.org/library/papers/38731446PubMed
738523032BCL-2 inhibition in haematological malignancies: Clinical application and complications.Blood Rev2024https://conductscience.org/library/papers/38523032PubMed
831346132Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.Oncologist2019https://conductscience.org/library/papers/31346132PubMed
934675185Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells.Cell Death Dis2021https://conductscience.org/library/papers/34675185PubMed
1033358111Targeting the Mevalonate Pathway in Cancer.Trends Cancer2021https://conductscience.org/library/papers/33358111PubMed
1132888407Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet2020https://conductscience.org/library/papers/32888407PubMed
1228362175Synergistic Impact of d-δ-Tocotrienol and Geranylgeraniol on the Growth and HMG CoA Reductase of Human DU145 Prostate Carcinoma Cells.Nutr Cancer2017https://conductscience.org/library/papers/28362175PubMed
1323291630ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.Nat Med2013https://conductscience.org/library/papers/23291630PubMed
1435267408Therapeutic Potential of Certain Terpenoids as Anticancer Agents: A Scoping Review.Cancers (Basel)2022https://conductscience.org/library/papers/35267408PubMed
1530135071Non-Hodgkin lymphoma.BMJ2018https://conductscience.org/library/papers/30135071PubMed
1638812137[Study on mechanism of inhibiting proliferation of head and neck cancer cells by citral, active ingredient of lemon essential oil].Zhongguo Zhong Yao Za Zhi2024https://conductscience.org/library/papers/38812137PubMed
1726576807
Open three-stage transthoracic oesophagectomy versus minimally invasive thoraco-laparoscopic oesophagectomy for oesophageal cancer: protocol for a multicentre prospective, open and parallel, randomised controlled trial.
BMJ Open2015https://conductscience.org/library/papers/26576807PubMed
1819399780AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.J Comput Chem2009https://conductscience.org/library/papers/19399780PubMed
1918219762Terpenes: substances useful in human healthcare.Arch Immunol Ther Exp (Warsz)2007https://conductscience.org/library/papers/18219762PubMed
2039036553Etiology of non-Hodgkin lymphoma: A review from epidemiologic studies.J Natl Cancer Cent2022https://conductscience.org/library/papers/39036553PubMed

See all 53 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42354121A Comprehensive Review of Bioactive Constituents, Health-Promoting Effects, Processing Technologies, and Industrial Applications of Sparassis crispa Sensu Lato.Foods2026https://conductscience.org/library/papers/42354121PubMed
42255243A systematic evaluation of double-expressor lymphoma: prognostic impact, determinants of outcome, and comparative efficacy and safety of novel therapies.Front Oncol2026https://conductscience.org/library/papers/42255243PubMed
42196355Essential Oils as a Source of Anticancer Molecules: Critical Assessment of Current Evidence and Methodological Limitations-A Systematic Review.Int J Mol Sci2026https://conductscience.org/library/papers/42196355PubMed
41011134Expanding the Knowledge of the Molecular Effects and Therapeutic Potential of Incomptine A for the Treatment of Non-Hodgkin Lymphoma: In Vivo and Bioinformatics Studies, Part III.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41011134PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
HMGCR3156PubTator's text mininghttps://conductscience.org/library/genes/3156

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40565145

GET https://conductscience.org/api/papers/v1/40565145/references?page=2